000			03307nam a22004815i 4500
001			978-3-540-31209-3
003			DE-He213
005			20161121230740.0
007			cr nn 008mamaa
008			100301s2007 gw | s |||| 0|eng d
020			_a9783540312093 _9978-3-540-31209-3
024	7		_a10.1007/978-3-540-31209-3 _2doi
050		4	_aRC261-271
072		7	_aMJCL _2bicssc
072		7	_aMED062000 _2bisacsh
082	0	4	_a614.5999 _223
245	1	0	_aTargeted Interference with Signal Transduction Events _h[electronic resource] / _cedited by Bernd Groner.
264		1	_aBerlin, Heidelberg : _bSpringer Berlin Heidelberg, _c2007.
300			_aIX, 188 p. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	1		_aResent Results in Cancer Research, _x0080-0015 ; _v172
505	0		_aIntroduction: The Rationale for the Development of Targeted Drugs in Cancer Therapy -- Identifying Critical Signaling Molecules for the Treatment of Cancer -- Tyrosine Kinase Inhibitors and Cancer Therapy -- Targeting ERBB Receptors in Cancer -- Inhibition of the IGF-I Receptor for Treatment of Cancer. Kinase Inhibitors and Monoclonal Antibodies as Alternative Approaches -- Inhibition of the TGF-? Signaling Pathway in Tumor Cells -- The Mammalian Target of Rapamycin Kinase and Tumor Growth Inhibition -- The Ras Signalling Pathway as a Target in Cancer Therapy -- The Mitogen-Activated Protein Kinase Pathway for Molecular-Targeted Cancer Treatment -- Clinical Relevance of Targeted Interference with Src-Mediated Signal Transduction Events.
520			_aSequencing of the human genome and insights into signaling pathways have contributed to the understanding of cancer etiology and the development of new, improved cancer drugs. DNA mutations of a limited set of genes are responsible for the multiple stages of tumorigenesis and metastasis. Matching of therapeutic intervention with insights into the underlying molecular disease mechanism has led to the development of drugs such as Herceptin and Glivec. The deregulation of pathways due to mutated cancer genes provides the conceptual basis for future progress. Will it be possible to extrapolate this principle and derive more efficient drugs targeting cancer pathway components? Potential drug targets have been identified, but our ability to predict the consequences of inhibition of such components is still limited. The state of development of tomorrow’s cancer drugs, directed against growth factors, growth factor receptors and intracellular signaling molecules with kinase activities, is described in this book.
650		0	_aMedicine.
650		0	_aCancer research.
650		0	_aMolecular biology.
650		0	_aOncology.
650	1	4	_aBiomedicine.
650	2	4	_aCancer Research.
650	2	4	_aOncology.
650	2	4	_aMolecular Medicine.
700	1		_aGroner, Bernd. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783540312086
830		0	_aResent Results in Cancer Research, _x0080-0015 ; _v172
856	4	0	_uhttp://dx.doi.org/10.1007/978-3-540-31209-3
912			_aZDB-2-SME
950			_aMedicine (Springer-11650)
999			_c503401 _d503401